News

The FDA has approved Zegfrovy (sunvozertinib) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment ...